Sitemap

June 05, 2006 Articles

Filter by Available Specialty
  1. Bevasiranib effective at all dose levels, study finds
  2. Deep sclerectomy, MMC ineffective in West African population
  3. FDA advisory committee rejects bone growth stimulator reclassification petition
  4. Pseudoexfoliation syndrome difficult to study
  5. Quarterly dosing with ranibizumab may not be ideal